Phase 3 Study of Dalbavancin for Acute Bacterial Infections of the Skin - ONA
Links shared publicly online about this topic.
- 306total visits
Phase 3 Study of Dalbavancin for Acute Bacterial Infections of the Skin - ONA
View full resource at oncologynurseadvisor.com
Tags: Skin, Infection, Bacterial Infection, Phase 3 Clinical Trial
Most Recently Shared on May 9, 2011 at 2:43 pm By:
Phase 3 Study of Dalbavancin for Acute Bacterial Infections of the Skin http://goo.gl/fb/7CU8n
Phase 3 Study of Dalbavancin for Acute Bacterial Infections of the Skin - MPR
empr.com — “Durata Therapeutics announced retrospective data from its Phase 3 study of dalbavancin for the treatment of acute bacterial infections of the skin.” View full resource at empr.com
Most Recently Shared on May 9, 2011 at 3:18 pm By:
MPR News: Phase 3 Study of Dalbavancin for Acute Bacterial Infections of the Skin: Durata Therapeutics announced... http://bit.ly/kBbVTx
Durata commences dalbavancin Phase 3 study in acute bacterial skin and skin structure infections
news-medical.net — “Durata Therapeutics today announced the Company initiated a global, pivotal, Phase 3 study (DISCOVER-1) of its lead product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections (abSSSI). The pivotal study is being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA).” View full resource at news-medical.net
Most Recently Shared on April 20, 2011 at 10:12 am By:
Durata commences dalbavancin Phase 3 study in acute bacterial skin and skin structure infections: Durata Therape... http://bit.ly/eVjlet
Phase 3 study of torezolid for acute bacterial skin and skin structure infections - MPR
empr.com — “Trius Therapeutics announced the initiation of its Phase 3 study of oral torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI).” View full resource at empr.com
Most Recently Shared on August 30, 2010 at 9:59 pm By:
MPR News: Phase 3 study of torezolid for acute bacterial skin and skin structure infections: Trius Therapeutics an... http://bit.ly/d9XLAi
Trius Therapeutics reaches agreement with FDA under SPA for Phase 3 study of torezolid phosphate for ABSSSI
news-medical.net — “Trius Therapeutics, Inc. announced today that it has reached agreement with the United States Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of its planned Phase 3 study for the oral dosage form of torezolid phosphate for treatment of acute bacterial skin and skin structure infections (ABSSSI).” View full resource at news-medical.net
Most Recently Shared on June 16, 2010 at 2:13 pm By:
Trius Therapeutics reaches agreement with FDA under SPA for Phase 3 study of torezolid phosphate for ABSSSI: Trius... http://bit.ly/doWvWo
Phase 2/3 study of CEM-102 for the treatment of acute bacterial skin structure infections (ABSSI) - MPR
empr.com — “Cempra Pharmaceuticals announced that enrollment is underway in its Phase 2/3 trial with CEM-102 for patients suffering from acute bacterial skin structure infections (ABSSI).” View full resource at empr.com
Most Recently Shared on September 9, 2009 at 7:25 pm By:
MPR News: Phase 2/3 study of CEM-102 for the treatment of acute bacterial skin structure infections (AB.. http://bit.ly/wNjUD
Advertisement
